Avai Bio (AVAI) Cost of Revenue (2020 - 2025)

Avai Bio has disclosed Cost of Revenue across 5 years of filings, most recently posting $55050.0 for Q4 2025.

• Cost of Revenue for Q4 2025 came in at $55050.0, up 2159.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $301604.0 (up 311.12% YoY), and the FY2025 annual result was $85164.0, up 182.53% from the prior year.
• Cost of Revenue came in at $55050.0 for Q4 2025 at Avai Bio, down from $80561.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $331253.0 in Q4 2021 to a low of $2436.0 in Q4 2024.
• The 4-year median for Cost of Revenue is $91713.5 (2022), against an average of $117866.4.
• Across the five-year window, Cost of Revenue tumbled 95.18% in 2022 and soared 2159.85% in 2025, its largest moves.
• Avai Bio's Cost of Revenue stood at $331253.0 in 2021, then plunged by 35.42% to $213912.0 in 2022, then sank by 98.86% to $2436.0 in 2024, then jumped by 2159.85% to $55050.0 in 2025.
• The last three Cost of Revenue figures came in at $55050.0 (Q4 2025), $80561.0 (Q3 2025), and $154190.0 (Q2 2025), per Business Quant data.